USFDA conducts inspection at Alembic Pharmaceuticals’ Oncology Formulation Facility

09 Mar 2024 Evaluate

United States Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals’ Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav from February 28, 2024 to March 8, 2024. The USFDA issued a Form 483 with four procedural observations. The company will provide comprehensive response to USFDA for the observations within the stipulated period.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.


Alembic Pharma Share Price

852.30 -4.95 (-0.58%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×